| Operations and Assets for Operating Segments and Geographic Information |
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
For the three months ended March 31, |
| (In thousands) |
|
|
|
|
2021 |
|
2020 |
| Revenue from services: |
|
|
|
|
|
|
|
| Pharmaceutical |
|
|
|
|
$ |
— |
|
|
$ |
— |
|
| Diagnostics |
|
|
|
|
506,951 |
|
|
170,839 |
|
| Corporate |
|
|
|
|
— |
|
|
— |
|
|
|
|
|
|
$ |
506,951 |
|
|
$ |
170,839 |
|
| Revenue from products: |
|
|
|
|
|
|
|
| Pharmaceutical |
|
|
|
|
$ |
33,945 |
|
|
$ |
31,074 |
|
| Diagnostics |
|
|
|
|
— |
|
|
— |
|
| Corporate |
|
|
|
|
— |
|
|
— |
|
|
|
|
|
|
$ |
33,945 |
|
|
$ |
31,074 |
|
| Revenue from transfer of intellectual property and other: |
|
|
|
|
|
|
|
| Pharmaceutical |
|
|
|
|
$ |
4,269 |
|
|
$ |
9,553 |
|
| Diagnostics |
|
|
|
|
— |
|
|
— |
|
| Corporate |
|
|
|
|
— |
|
|
— |
|
|
|
|
|
|
$ |
4,269 |
|
|
$ |
9,553 |
|
| Operating income (loss): |
|
|
|
|
|
|
|
| Pharmaceutical |
|
|
|
|
$ |
(19,157) |
|
|
$ |
(14,126) |
|
| Diagnostics |
|
|
|
|
67,014 |
|
|
(18,133) |
|
| Corporate |
|
|
|
|
(9,420) |
|
|
(8,503) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
38,437 |
|
|
$ |
(40,762) |
|
| Depreciation and amortization: |
|
|
|
|
|
|
|
| Pharmaceutical |
|
|
|
|
$ |
7,413 |
|
|
$ |
7,121 |
|
| Diagnostics |
|
|
|
|
12,576 |
|
|
14,871 |
|
| Corporate |
|
|
|
|
— |
|
|
60 |
|
|
|
|
|
|
$ |
19,989 |
|
|
$ |
22,052 |
|
| Loss from investment in investees: |
|
|
|
|
|
|
|
| Pharmaceutical |
|
|
|
|
$ |
(43) |
|
|
$ |
(134) |
|
| Diagnostics |
|
|
|
|
— |
|
|
— |
|
| Corporate |
|
|
|
|
— |
|
|
— |
|
|
|
|
|
|
$ |
(43) |
|
|
$ |
(134) |
|
| Revenues: |
|
|
|
|
|
|
|
| United States |
|
|
|
|
$ |
512,871 |
|
|
$ |
180,872 |
|
| Ireland |
|
|
|
|
7,129 |
|
|
11,901 |
|
| Chile |
|
|
|
|
14,152 |
|
|
10,850 |
|
| Spain |
|
|
|
|
5,919 |
|
|
4,156 |
|
| Israel |
|
|
|
|
2,512 |
|
|
1,707 |
|
| Mexico |
|
|
|
|
2,418 |
|
|
1,841 |
|
| Other |
|
|
|
|
164 |
|
|
139 |
|
|
|
|
|
|
$ |
545,165 |
|
|
$ |
211,466 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| (In thousands) |
March 31,
2021 |
|
December 31,
2020 |
| Assets: |
|
|
|
| Pharmaceutical |
$ |
1,151,771 |
|
|
$ |
1,176,245 |
|
| Diagnostics |
1,330,183 |
|
|
1,268,738 |
|
| Corporate |
37,621 |
|
|
28,080 |
|
|
$ |
2,519,575 |
|
|
$ |
2,473,063 |
|
| Goodwill: |
|
|
|
| Pharmaceutical |
$ |
241,353 |
|
|
$ |
245,793 |
|
| Diagnostics |
434,809 |
|
|
434,809 |
|
| Corporate |
— |
|
|
— |
|
|
$ |
676,162 |
|
|
$ |
680,602 |
|
|